Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Mitsuhisa Takatsuki x
Clear All Modify Search
Authors: Fumihiko Fujita, Yasuhiro Torashima, Yusuke Inoue, Shinichiro Ito, Kazuma Kobayashi, Kengo Kanetaka, Mitsuhisa Takatsuki and Susumu Eguchi

Background and aims

The aim of this study is to exploratively evaluate the effect of Tsumura Daikenchuto Extract Granules (DKT, TJ-100) on abdominal symptoms, body weight, and nutritional function following colorectal cancer surgery.

Methods

The subjects included 20 patients for curative resection of colorectal cancer. A TJ-100 administration group (n = 10) and non-administration group (n = 10) were randomized and compared. In the administration group, TJ-100 was administered from 2 days prior to surgery up to 12 weeks following surgery. The endpoints included body weight gain, Gastrointestinal Symptom Rating Scale (GSRS), and blood biochemical factors. For the purpose of observing safety, drug adverse events were evaluated including liver function tests.

Results

Excluding one patient, we compared 9 cases in the administration group and 10 cases in the non-administration group. No obvious adverse events were observed in any of the cases. In the comparison of body weight gain, the TJ-100 administration group showed significantly higher values at 2, 4, and 12 weeks following the surgery. There was a tendency for lower stable GSRS scores in the administration group overall, with no statistically significant difference.

Conclusion

It is suggested that TJ-100 can be safely administered in the perioperative period for cases undergoing colorectal cancer surgery, potentially preventing weight loss during the early postoperative period.

Open access
Authors: Koji Hamasaki, Susumu Eguchi, Tatsuki Ichikawa, Mitsuhisa Takatsuki, Masaaki Hidaka, Kosho Yamanouchi, Kensuke Miyazaki, Takamitsu Inokuma and Takashi Kanematsu

Abstract

Background/Aim

Although a recurrent hepatitis C virus (HCV) infection is the leading cause of graft loss in liver transplant recipients, the optimal timing to begin interferon (IFN) therapy after LTx is still unknown. The purpose of this study is to analyze the relationships, between signaling by PEGylated IFN in human hepatocytes, with regard to hepatocyte proliferation, and immunosuppressive drugs in vitro.

Methods

Experiment 1 — Normal human hepatocytes (NhHeps) were cultured with/without recombinant human hepatocyte growth factor (r-hHGF) for 48 h, and then treated with 100 IU/mL IFN at the indicated time. The expressions of double-stranded RNA-dependent protein kinase (PKR) and IFN-α-induced antiviral protein were analyzed using Western blotting for the extracted lysates from these cells. Experiment 2 — The NhHeps were cultured in 10% medium containing varying concentrations of tacrolims (Tac), cyclosporine A (CyA), and methylprednisolone (PLS), and the cells were treated with 100 IU/mL IFN at the indicated time. Subsequently, the density of PKR was examined. Results: The expression of PKR was enhanced by HGF. PKR induction by IFN was suppressed by Tac > CyA > PLS.

Conclusion

Hepatocyte proliferation induced by HGF did not interfere with the signaling by IFN. The presence of immunosuppressive drugs was therefore found to negatively affect IFN signaling.

Restricted access